# A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of HSK39004 Inhalation Suspension in Patients With COPD

> **NCT07658339** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Haisco Pharmaceutical Group Co., Ltd.** · enrollment: 387 (estimated)

## Conditions studied

- COPD (Chronic Obstructive Pulmonary Disease)

## Interventions

- **DRUG:** HSK39004 Inhalation Suspension
- **DRUG:** Placebo control

## Key facts

- **NCT ID:** NCT07658339
- **Lead sponsor:** Haisco Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-11
- **Primary completion:** 2027-06-11
- **Final completion:** 2027-06-11
- **Target enrollment:** 387 (ESTIMATED)
- **Last updated:** 2026-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07658339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07658339, "A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of HSK39004 Inhalation Suspension in Patients With COPD". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07658339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*